Literature DB >> 21367427

Developing a validated liquid chromatography-mass spectrometric method for the simultaneous analysis of five bioactive quassinoid markers for the standardization of manufactured batches of Eurycoma longifolia Jack extract as antimalarial medicaments.

Chin-Hoe Teh1, Vikneswaran Murugaiyah, Kit-Lam Chan.   

Abstract

An extensive comparative study on the electrospray ionization (ESI) and atmospheric pressure chemical ionization (APCI) mass spectrometry using automated flow injection analysis (FIA), was performed on eurycomanone (1), 13α(21)-epoxyeurycomanone (2), eurycomanol (3), eurycomanol-2-O-β-d-glucopyranoside (4), and 13,21-dihydroeurycomanone (5), the bioactive markers isolated from Eurycoma longifolia. The effects of eluent mixture (methanol or acetonitrile in water) and acidic modifiers (acetic acid, formic acid and trifluoroacetic acid) on the ionization efficiency of the markers were also investigated. The ESI in the positive ion mode with methanol containing 0.1% (v/v) acetic acid was selected for the subsequent optimization of nebulizer pressure, dry gas flow, dry gas temperature and capillary voltage to improve the sensitivity of the total ion chromatogram (TIC). Fragmentation of the analytes was further investigated by varying the capillary exit offset voltage and fragmentation amplitude in positive mode of ESI. The detection limits (LODs) were determined in isolation mode (selected ion monitoring, SIM). Their limits of detection (LODs) ranged between 0.03 and 0.1μgmL(-1) while the intra-day and inter-day precisions were less than 5.72% and 4.82%, respectively. The method was next applied for the simultaneous analysis of the markers to standardize various batches of manufactured extracts of E. longifolia for potential use as antimalarial products. Multiple Reaction Monitoring (MRM) mode was used for the quantification of analytes which gave protonated molecular ion, [M+H](+). For those without pseudo-molecular ions, SIM mode was used to quantify the analytes. The batches contained 5.65-9.95% of eurycomanone (1), 5.21-19.75% of eurycomanol (3) and 7.59-19.95% of eurycomanol-2-O-β-d-glucopyranoside (4) as major quassinoids whereas, 13α(21)-epoxyeurycomanone (2), and 13,21-dihydroeurycomanone (5) were much lower in concentrations of 0.78-3.90% and 0.47-1.76%, respectively.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21367427     DOI: 10.1016/j.chroma.2011.02.014

Source DB:  PubMed          Journal:  J Chromatogr A        ISSN: 0021-9673            Impact factor:   4.759


  4 in total

1.  The in vitro and in vivo anti-cancer activities of a standardized quassinoids composition from Eurycoma longifolia on LNCaP human prostate cancer cells.

Authors:  Kind Leng Tong; Kit Lam Chan; Sazaly AbuBakar; Bin Seng Low; Hai Qiu Ma; Pooi Fong Wong
Journal:  PLoS One       Date:  2015-03-31       Impact factor: 3.240

2.  In Vitro Evaluation of the Effects of Eurycoma longifolia Extract on CYP-Mediated Drug Metabolism.

Authors:  Young Min Han; In Sook Kim; Shaheed Ur Rehman; Kevin Choe; Hye Hyun Yoo
Journal:  Evid Based Complement Alternat Med       Date:  2015-07-09       Impact factor: 2.629

3.  Decreased expression of alpha-2-HS glycoprotein in the sera of rats treated with Eurycoma longifolia extract.

Authors:  Yeng Chen; Wai-Mei Phang; Alan K-W Mu; Choon-Keat Chan; Bin-Seng Low; Sreenivasan Sasidharan; Kit-Lam Chan
Journal:  Front Pharmacol       Date:  2015-09-23       Impact factor: 5.810

4.  Bioavailability of Eurycomanone in Its Pure Form and in a Standardised Eurycoma longifolia Water Extract.

Authors:  Norzahirah Ahmad; Dodheri Syed Samiulla; Bee Ping Teh; Murizal Zainol; Nor Azlina Zolkifli; Amirrudin Muhammad; Emylyn Matom; Azlina Zulkapli; Noor Rain Abdullah; Zakiah Ismail; Ami Fazlin Syed Mohamed
Journal:  Pharmaceutics       Date:  2018-07-11       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.